How argenx Is Reinventing Autoimmune Treatment | Dr. Luc Truyen, M.D., Ph.D., Chief Medical Officer, argenx

Send us Fan MailMost autoimmune drugs suppress the immune system broadly - but what if you could selectively remove the antibodies actually causing disease? That’s exactly what VYVGART is doing, and it may fundamentally change how we treat conditions like myasthenia gravis and CIDP.Dr. Luc Truyen, M.D., Ph.D., is Chief Medical Officer at argenx ( https://argenx.com/ ), where he leads the company’s global clinical development and medical strategy across a rapidly advancing portfolio of immunology and neuromuscular therapies.A neurologist by training, Dr. Truyen brings more than two decades of experience in drug development, with a particular focus on neuroscience, neuroimmunology, and complex CNS disorders. Before joining argenx in 2021, he spent over 20 years at Johnson & Johnson and its pharmaceutical division Janssen Pharmaceuticals, where he held multiple senior leadership roles.Most notably, Dr. Truyen served as Global Head of Development for Neuroscience at Janssen, overseeing early- and late-stage pipelines spanning mood disorders, schizophrenia, and neurodegenerative and neuroinflammatory diseases. He also led global external affairs efforts in Alzheimer’s disease, playing key roles in major international collaborations such as the Innovative Medicines Initiative and global dementia platforms.Earlier in his career, Dr. Truyen was Head of R&D and Chief Medical Officer of Janssen Alzheimer Immunotherapy, where he helped guide strategy across research, clinical development, and regulatory functions for novel immunotherapies targeting Alzheimer’s disease.At argenx, Dr. Truyen is now helping drive the expansion of VYVGART (efgartigimod), a first-in-class FcRn antagonist, across multiple indications including myasthenia gravis and chronic inflammatory demyelinating polyneuropathy (CIDP), while advancing a broader pipeline aimed at transforming treatment paradigms in autoimmune and neuromuscular diseases.Dr. Truyen earned both his M.D. and Ph.D. in Neurology from the University of Antwerp.#LucTruyen #argenx #VYVGART #efgartigimod #MyastheniaGravis #CIDP #AutoimmuneDisease #Neurology #Biotech #Pharma #DrugDevelopment #FcRn #Immunology #RareDisease #ClinicalTrials #AAN2026 #MedicalInnovation #HealthcareInnovation #BiotechPodcast #LifeSciences #Neuroimmunology #IVIG #PrecisionMedicine #FutureOfMedicineSupport the show